DENVER, Colo., Apr 18, 2024 (247marketnews.com)- Benitec Biopharma Inc. (NASDAQ:BNTC) reported positive interim clinical data and a private investment from the sale of 5,749,152 shares of its common stock at a price per share of $4.80 and 2,584,239 pre-funded warrants at $4.7999, for a total of approximately $40 million, before deducting offering expenses.

The 90-day timepoint clinical data follows the administration of BB-301 to the study's first subject treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study (NCT06185673) in Oculopharyngeal Muscular Dystrophy (OPMD).

"To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing. We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301," said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. "We are highly encouraged by these early clinical trial results and for the hope that they may offer to patients and caregivers, and we look forward to reporting additional results and continuing to treat patients as they enter the dosing portion of the study from the Natural History observational lead-in period."

The post Benitec Biopharma Reports Positive Interim Phase 1b/2a Clinical Trial Data and Oversubscribed $40M Private Placement appeared first on 24/7 MarketNews.

COMTEX_451345568/2900/2024-04-24T11:16:26